Other Publication Details
Mandatory Fields
Reviews
Hombach-Klonisch, S;Mehrpour, M;Shojaei, S;Harlos, C;Pitz, M;Hamai, A;Siemianowicz, K;Likus, W;Wiechec, E;Toyota, BD;Hoshyar, R;Seyfoori, A;Sepehri, Z;Ande, SR;Khadem, F;Akbari, M;Gorman, AM;Samali, A;Klonisch, T;Ghavami, S
2018
April
Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response
Published
1
Optional Fields
ENDOPLASMIC-RETICULUM-STRESS STEM-LIKE CELLS BASE EXCISION-REPAIR BEVACIZUMAB PLUS IRINOTECAN RANDOMIZED PHASE-III TEMOZOLOMIDE-INDUCED CYTOTOXICITY NEWLY-DIAGNOSED GLIOBLASTOMA RESISTANT GLIOMA-CELLS TUMOR-INITIATING CELLS CENTRAL-NERVOUS-SYSTEM
Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment of brain tumors remains a challenge. This is particularly true for the most frequent and fatal adult brain tumor, glioblastoma (GB). Upon diagnosis, the average survival time of GB patients remains only approximately 15 months. The alkylating drug temozolomide (TMZ) is routinely used in brain tumor patients and induces apoptosis, autophagy and unfolded protein response (UPR). Here, we review these cellular mechanisms and their contributions to TMZ chemoresistance in brain tumors, with a particular emphasis on TMZ chemoresistance in glioma stem cells and GB.
OXFORD
PERGAMON-ELSEVIER SCIENCE LTD
0163-7258
13
41
10.1016/j.pharmthera.2017.10.017
Grant Details
Publication Themes